Corine Cj Van Marrewijk

List of Publications by Year
in descending order

30 papers	1,912 citations	686830 13 h-index	610482 24 g-index
30 all docs	30 docs citations	30 times ranked	1243 citing authors

#	Article	IF	Citations
1	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. Leukemia, 2021, 35, 1745-1750.	3.3	15
2	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. Blood Advances, 2021, 5, 3066-3075.	2.5	12
3	Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists. Blood Advances, 2021, , .	2.5	6
4	Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset. Blood, 2021, 138, 4671-4671.	0.6	0
5	Validation of the Qualms Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project. Blood, 2021, 138, 1982-1982.	0.6	1
6	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica, 2020, 105, 632-639.	1.7	35
7	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica, 2020, 105, 640-651.	1.7	32
8	Development of a core outcome set for myelodysplastic syndromes â€“ a Delphi study from the EUMDS Registry Group. British Journal of Haematology, 2020, 191, 405-417.	1.2	10
9	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. Haematologica, 2020, 105, 2516-2523.	1.7	12
10	Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints. Blood, 2020, 136, 29-29.	0.6	2
11	Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 838-845.	0.6	19
12	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. Leukemia Research, 2018, 67, 21-26.	0.4	4
13	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia, 2018, 32, 1380-1392.	3.3	66
14	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica, 2018, 103, 69-79.	1.7	35
15	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. Blood Advances, 2018, 2, 2079-2089.	2.5	18
16	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. Blood, 2018, 132, 4357-4357.	0.6	1
17	Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival. Blood, 2018, 132, 4392-4392.	0.6	0
18	Longitudinal Changes of Impairments in Health-Related Quality of Life in Lower-Risk MDS Patients: A European Leukemianet Study. Blood, 2018, 132, 3097-3097.	0.6	0

#	Article	IF	Citations
19	Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death. Blood, 2018, 132, 4385-4385.	0.6	1
20	Deriving Core Patient-Reported Outcomes in Patients with Myelodysplastic Syndromes â€" a Delphi Survey from the European-MDS Registry. Blood, 2018, 132, 2295-2295.	0.6	0
21	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. Blood, 2016, 128, 3186-3186.	0.6	14
22	Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. Blood, 2015, 126, 2865-2865.	0.6	3
23	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. Blood, 2015, 126, 1677-1677.	0.6	0
24	Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. Blood, 2014, 124, 3267-3267.	0.6	0
25	Diameter of abdominal aortic aneurysm and outcome of endovascular aneurysm repair: does size matter? A report from EUROSTAR. Journal of Vascular Surgery, 2004, 39, 288-297.	0.6	265
26	The significance and management of different types of endoleaks. Seminars in Vascular Surgery, 2003, 16, 95-102.	1.1	112
27	Life expectancy after endovascular versus open abdominal aortic aneurysm repair: Results of a decision analysis model on the basis of data from EUROSTAR. Journal of Vascular Surgery, 2002, 36, 1112-1120.	0.6	65
28	Significance of endoleaks after endovascular repair of abdominal aortic aneurysms: The EUROSTAR experience. Journal of Vascular Surgery, 2002, 35, 461-473.	0.6	446
29	Causes and outcomes of open conversion and aneurysm rupture after endovascular abdominal aortic aneurysm repair: can type ii endoleaks be dangerous?11No competing interests declared.. Journal of the American College of Surgeons, 2002, 194, S98-S102.	0.2	47
30	Incidence and risk factors of late rupture, conversion, and death after endovascular repair of infrarenal aortic aneurysms: The EUROSTAR experience. Journal of Vascular Surgery, 2000, 32, 739-749.	0.6	691